New therapies for type 2 diabetes based on glucagon-like peptide 1
Cleveland Clinic Journal of Medicine. 2006 April;73(4):382-389
April 1, 2006|Cleveland Clinic Journal of Medicine
Author and Disclosure Information
ABSTRACTCells in the gastrointestinal tract secrete several hormones that stimulate insulin secretion, one of which is glucagon-like peptide (GLP-1). Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes. One such compound, exenatide (Byetta), has recently become available, and others are in clinical development.
